Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on February 21, 2006
Schizophrenia Bulletin 2006 32(2):234-237; doi:10.1093/schbul/sbj055
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
32/2/234    most recent
sbj055v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Erhart, S. M
Right arrow Articles by Carpenter, W. T
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erhart, S. M
Right arrow Articles by Carpenter, W. T
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Treatment of Schizophrenia Negative Symptoms: Future Prospects

Stephen M Erhart1,2–3,, Stephen R Marder2, 3, and William T Carpenter4
2 UCLA Department of Psychiatry and Biobehavioral Sciences
3 VISN 22 MIRECC, US Department of Veterans' Affairs
4 University of Maryland School of Medicine, Department of Psychiatry

1To whom correspondence should be addressed; e-mail: serhart{at}ucla.edu.

New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.

Keywords: negative symptoms / schizophrenia / treatment / construct validity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Psychiatr. Serv.Home page
A. Faerden, S. Friis, I. Agartz, E. A. Barrett, R. Nesvag, A. Finset, and I. Melle
Apathy and Functioning in First-Episode Psychosis
Psychiatr Serv, November 1, 2009; 60(11): 1495 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon
Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
Schizophr Bull, September 1, 2009; 35(5): 931 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
G. I. Elmer and N. Kafkafi
Drug Discovery in Psychiatric Illness: Mining for Gold
Schizophr Bull, March 18, 2009; (2009) sbn194v1.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
J. Kulkarni, A. de Castella, P. B. Fitzgerald, C. T. Gurvich, M. Bailey, C. Bartholomeusz, and H. Burger
Estrogen in Severe Mental Illness: A Potential New Treatment Approach
Arch Gen Psychiatry, August 1, 2008; 65(8): 955 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
G. Foussias and G. Remington
Negative Symptoms in Schizophrenia: Avolition and Occam's Razor
Schizophr Bull, July 21, 2008; (2008) sbn094v1.
[Abstract] [Full Text] [PDF]

Home page
 Psychiatr. Serv.Home page
D. C. Owens
What CATIE Did: Some Thoughts on Implications Deep and Wide
Psychiatr Serv, May 1, 2008; 59(5): 530 - 533.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
V. Curtis, K. Katsafouros, H-J. Moller, R. Medori, and E. Sacchetti
Long-acting risperidone improves negative symptoms in stable psychotic patients
J Psychopharmacol, May 1, 2008; 22(3): 254 - 261.
[Abstract] [PDF]

Home page
 Adv. Psychiatr. Treat.Home page
D. C. Owens
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Adv. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.